

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **Abattis Bioceuticals Corp.** (the "Issuer").

Trading Symbol: **FLU**

Number of Outstanding Listed Securities: **28,584,094**

Date: **August 27, 2013**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

For the month of July, the Issuer continued its negotiations with Borderland Bio-Diesel Ltd., doing business as Farm Genesis Group ("Farm Genesis") to enter into a definitive agreement as further described in Item 2 below.

2. Provide a general overview and discussion of the activities of management.

For the month of July, the Issuer continued working towards entering into a definitive agreement with Farm Genesis which will reflect the terms of the Transaction.

The terms of the Transaction are reiterated below.

It is anticipated that the Transaction is to be effected by way of a share purchase in which the Issuer will acquire 100% of the issued and outstanding share capital of Farm Genesis.

In exchange for the acquisition of the shares of Farm Genesis, the Issuer will pay the following as consideration in the Transaction:

- (a) **500,000 common shares of the Issuer to the shareholders of Farm Genesis *pro rata* to their shareholdings in Farm Genesis;**
- (b) **certain accounts payable by Farm Genesis, totalling a maximum of \$322,800;**
- (c) **approximately \$5,600 in interest owing by Farm Genesis on an outstanding loan;**
and,
- (d) **professional fees owing by Farm Genesis up to a maximum of \$52,000**

(collectively, the "Consideration").

Additionally, it is intended that the Issuer will acquire certain bottling machinery currently owned by Farm Genesis for the separate consideration of payments to a third party on behalf of Farm Genesis. Pursuant to the letter of intent between the Issuer and Farm Genesis, the amount to be paid will be negotiated between the Issuer and the third party. Farm Genesis is located in Waskada, MB also known as hemp country. Farm Genesis owns a hemp license and a 25,000 sq ft building designed for hemp processing on just over 3 acres of land. Farm Genesis also has ownership in an advanced proprietary extraction technology company.

Upon completion of the Transaction, the Issuer will assume the outstanding debts of Farm Genesis, including the outstanding loan noted in paragraph (c) above.

Completion of the Transaction is subject to the approval of the Canadian National Stock Exchange, the boards of directors of the Issuer and Farm Genesis and the shareholders of Farm Genesis. Completion of the Transaction is further subject to the Issuer receiving financing to pay the Consideration and standard closing conditions and requirements.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer developed its Nitric Oxide formula during the month of April 2012 and continued to prepare for the product launch in the second quarter of fiscal 2013. Since December 2012 and through June 2013, the Issuer has been actively involved in engaging certain field experts to assist the Issuer with obtaining the licensing for marijuana “cannabis” for the use in the Medical Marijuana industry in Canada and in United States. (Refer to Form 7 for March 2013.)

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provides details of the relationship.

The Transaction in Item 2 above will be an arm’s-length transaction and will be subject to the approval of the boards of directors of the Issuer and Farm Genesis and the shareholders of Farm Genesis.

8. Describe the acquisition of new customers or loss of customers.

N/A

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

N/A

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Anny Chen, Corporate Secretary left the company to pursue other opportunities

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Since January 2013, the Issuer has been dealing with a claim made by a former consultant and took the position: there is no merit to this claim. The claim is for the amount of \$30,000, which the claimant noted as compensation for his service in the original application filed on December 4, 2012. The present status of the claim is that the Issuer filed a Response, and the claim proceeded further in BC small claims court mediation on July 15, 2013.

On April 8, 2013, the Issuer began to deal with another claim made by a business partner of the former consultant. The claim is for the amount of \$30,000, which the claimant noted as compensation for his service in the original application. A Reply was filed on April 22, 2013.

The Issuer believes both of these claims to have no merit and date back to the days prior management controlled the company.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

N/A

15. Provide details of any loans to or by Related Persons.

The CEO of the Issuer continued to advance funds on a short term basis.

16. Provide details of any changes in directors, officers or committee members.

N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Issuer's audited financial statements and corresponding Managements' Discussion & Analysis for the year ended September 30, 2012, which are filed on SEDAR effective February 28, 2013.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 27, 2013 _____.

Michael Withrow
Name of Director or Senior Officer

"Michael Withrow"
Signature

President & CEO
Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer		July 2013	YY/MM/DD
Abattis Bioceticals Corp.			13/08/27
Issuer Address			
Suite 1000 – 355 Burrard Street			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C 2G8		(604) 888-1519	(604) 538-6650
Contact Name		Contact Position	Contact Telephone No.
Mike Withrow		President, CEO & Director	(604) 538-6650
Contact Email Address		Web Site Address	
mike.withrow@abattis.com		www.abattis.com	